Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.29 +1.37 (+1.03%)
Streaming Delayed Price Updated: 2:06 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
46 47 Next >
UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients. 
Via Benzinga
S&P 500's surge to new highs: Bull trap hiding in plain sight?
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers. 
Via MarketBeat
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development. 
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Novo Nordisk Unusual Options Activity For February 14
Via Benzinga
NYSE:NVO is not too expensive for the growth it is showing.
Investors seeking growth at a reasonable cost should explore NYSE:NVO. 
Via Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
Don't let the stock's high price deceive you -- Novo Nordisk can still make for a great investment. 
Via The Motley Fool
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
It faces both clinical and competitive barriers, but they might not matter. 
Via The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble. 
Via InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position 
Via Benzinga
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
There's more for investors to get excited about in the biopharma world than just weight-loss drugs. 
Via The Motley Fool
Prediction: 2 Stocks That Could Trounce the Market
They have done it before. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk's Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement
Findings on diabetes and weight loss drugs in hip replacement. Novo Nordisk's Ozempic shows a 44% reduction in joint infections, and Wegovy proves safe, reducing complications. 
Via Benzinga
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Novo Nordisk's Magic Run Continues Even With Increasing Competition
Novo Nordisk's Q4 earnings were rock solid as momentum in the diabetes and obesity markets continued to fuel growth. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market... 
Via Benzinga
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
Via The Motley Fool
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
Everyone is excited about Zepbound, from patients to investors... 
Via The Motley Fool
Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk, plans to ramp up its annual investments to $7 billion by 2030. 
Via Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
Even more revenue is on the way from additional sales of Wegovy. 
Via The Motley Fool
Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.
Novo Nordisk stock is up more than 70% in the past year thanks to the success of Ozempic, Rybelsus, and Wegovy. 
Via The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic. 
Via The Motley Fool
3 Stocks That Could Trounce the Market in 2024
These stocks appear to have what it takes to beat the market this year. 
Via The Motley Fool
S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets
The S&P 500 index surged past 5,000, led by tech giants. Tesla falls to ninth in market cap, Novo Nordisk disrupts food industry, Ackman targets retail investors. 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company. 
Via Benzinga
How Important Are Ozempic and Wegovy to Novo Nordisk's Business?
Does a lack of diversification make Novo Nordisk a risky buy? 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
46 47 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.